Does the MTHFR rs1801131 AC genotype modestly reduce enzyme activity without proving impaired methylation or higher cardiovascular risk?

At age 52, an MTHFR rs1801131 (A1298C) AC result is best understood as a modest biochemical susceptibility, not a diagnosis of impaired methylation or a cardiovascular-risk condition.

Functional and mechanistic evidence

• Human lymphocyte-extract data place MTHFR activity in AC carriers at approximately 80–83% of AA activity—a roughly 15–20% reduction. The A1298C substitution (E429A) lies in the enzyme’s C-terminal regulatory domain; experimental variant protein retains about 68% of wild-type activity and is not thermolabile.
• MTHFR converts 5,10-methylene-THF to 5-methyl-THF, which supplies the methyl group for vitamin-B12-dependent methionine synthase remethylation of homocysteine. This pathway supports methionine/SAM production, but a modest enzyme-activity difference does not demonstrate impaired methylation in an individual.

Clinical interpretation

• Common A1298C testing has minimal routine clinical utility. AC status alone does not consistently raise homocysteine, establish an abnormal DNA-methylation state, or justify treatment.
• Plasma total homocysteine can help identify a functional disturbance in folate/B12-dependent remethylation, but it is nonspecific. Folate or B12 deficiency, reduced renal function, B6 status, medications, diet, age, lifestyle, and sample handling can affect it. A concentration above roughly 15 µmol/L is commonly termed hyperhomocysteinemia, interpreted using laboratory and renal context.
• If clinically indicated, CBC, folate, B12, and selected MMA and/or homocysteine testing are more informative than genotype alone; elevated MMA more specifically supports B12 deficiency.

Cardiovascular implications

• A systematic review of 47 myocardial-infarction studies and meta-prediction evidence found no significant overall A1298C association with myocardial infarction or ischemic heart disease. It should not reclassify cardiovascular risk.

Bottom line

• AC genotype may modestly lower MTHFR activity, but it neither proves impaired methylation nor independently increases cardiovascular risk. Homocysteine is a contextual functional marker, not evidence that the genotype is the cause of an abnormal result.